Auburn University

Ludmila Globa

Vitaly J Vodyanoy

Henry J Baker

Tatiana I Samoylova

Nancy R Cox

Edward E Morrison

Nilmini Viswaprakash

Alexandre M Samoylov

Nancy E Morrison

Lewis G Scharpf

Oleg Pustovyy

Valery A Petrenko

Iryna Sorokulova

Brenda Griffin

Kristina Pendergrass

Mahmoud Mansour

M Daniel Givens

Kay P Riddell

A pharmaceutical composition comprises a metal nanoparticle having an average diameter of about 0.5 nm to about 5 nm. The composition may be used to treat cancer or an anosmia-related disease.

Engineered metal nanoparticles and methods thereof

A composition, system and method for modifying an olfactory response to an odorant is disclosed. In some embodiments, the composition includes crystalline metal nanoparticles dispersed in an aqueous medium. The composition is applied to olfactory tissues using a suitable applicator or dispenser. The metal nanoparticles are believed to interact with a G-protein coupled to receptor located in the cilia to moderate (enhance or reduce) sensitivity or ability to smell particular odorants. In accordance with an embodiment of the invention, the composition includes one or more odorants.

Compositions for and methods of controlling olfactory responses to odorants

Disclosed are methods, compositions, and zona pellucida binding peptides and polypeptides for use in immunocontraception of canines and other animals. The disclosed compositions may include pharmaceutical compositions. Methods for identifying peptides that bind to intact oocytes also are provided, in particular methods for identifying peptides that bind to zona pellucida of intact oocytes.

Methods for identifying peptides that bind to intact oocytes

A diagnostic technique for matching anti-cancer peptide drugs to the molecular profiles of individual cancer tumors, and a method using the technique for a patient-specific treatment of tumors in mammals. This strategy matches anti-cancer peptide drugs to the molecular profiles of individual tumors, and includes the development of two banks, both of which use the same targeting peptides. Targeting peptides are identified using biopsies or other tissue materials from multiple cancer patients and placed into two banks. For a bank of probes, targeting peptides are linked to a label such as a fluorescent or a radioisotope. For a bank of drugs, targeting peptides are linked to a cytotoxic peptide to form a 'targeting peptide drug'. Peptide probes are used to establish molecular profiles of individual tumors. Based on these molecular profiles, a patient-specific combination of targeting drugs from the bank of peptide drugs is prepared and the patient is treated. Any currently used cytotoxic agent that can be linked to targeting peptides may be used in place of cytotoxic peptides.

Methods for targeting and killing glioma cells

Compositions for use in characterization, diagnosis, prognosis, and therapy of cancer cells are provided. The compositions comprise peptides and variants thereof which were isolated based on their ability to selectively bind glioma cells.

Peptides for recognition and targeting of GLIAL cell tumors

Growing community of inventors

Auburn, AL, United States of America

Ludmila Globa